168 related articles for article (PubMed ID: 24036541)
21. B cell antigen receptor-mediated activation of cyclin-dependent retinoblastoma protein kinases and inhibition by co-cross-linking with Fc gamma receptors.
Tanguay D; Pavlovic S; Piatelli MJ; Bartek J; Chiles TC
J Immunol; 1999 Sep; 163(6):3160-8. PubMed ID: 10477583
[TBL] [Abstract][Full Text] [Related]
22. A dominant-negative cyclin D1 mutant prevents nuclear import of cyclin-dependent kinase 4 (CDK4) and its phosphorylation by CDK-activating kinase.
Diehl JA; Sherr CJ
Mol Cell Biol; 1997 Dec; 17(12):7362-74. PubMed ID: 9372967
[TBL] [Abstract][Full Text] [Related]
23. Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis.
Masaki T; Shiratori Y; Rengifo W; Igarashi K; Yamagata M; Kurokohchi K; Uchida N; Miyauchi Y; Yoshiji H; Watanabe S; Omata M; Kuriyama S
Hepatology; 2003 Mar; 37(3):534-43. PubMed ID: 12601350
[TBL] [Abstract][Full Text] [Related]
24. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity.
Ali S; Heathcote DA; Kroll SH; Jogalekar AS; Scheiper B; Patel H; Brackow J; Siwicka A; Fuchter MJ; Periyasamy M; Tolhurst RS; Kanneganti SK; Snyder JP; Liotta DC; Aboagye EO; Barrett AG; Coombes RC
Cancer Res; 2009 Aug; 69(15):6208-15. PubMed ID: 19638587
[TBL] [Abstract][Full Text] [Related]
25. The crystal structure of human CDK7 and its protein recognition properties.
Lolli G; Lowe ED; Brown NR; Johnson LN
Structure; 2004 Nov; 12(11):2067-79. PubMed ID: 15530371
[TBL] [Abstract][Full Text] [Related]
26. Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors.
Kalan S; Amat R; Schachter MM; Kwiatkowski N; Abraham BJ; Liang Y; Zhang T; Olson CM; Larochelle S; Young RA; Gray NS; Fisher RP
Cell Rep; 2017 Oct; 21(2):467-481. PubMed ID: 29020632
[TBL] [Abstract][Full Text] [Related]
27. Cyclin-dependent kinase-2 (Cdk2) forms an inactive complex with cyclin D1 since Cdk2 associated with cyclin D1 is not phosphorylated by Cdk7-cyclin-H.
Higashi H; Suzuki-Takahashi I; Saitoh S; Segawa K; Taya Y; Okuyama A; Nishimura S; Kitagawa M
Eur J Biochem; 1996 Apr; 237(2):460-7. PubMed ID: 8647086
[TBL] [Abstract][Full Text] [Related]
28. The cryoelectron microscopy structure of the human CDK-activating kinase.
Greber BJ; Perez-Bertoldi JM; Lim K; Iavarone AT; Toso DB; Nogales E
Proc Natl Acad Sci U S A; 2020 Sep; 117(37):22849-22857. PubMed ID: 32855301
[TBL] [Abstract][Full Text] [Related]
29. Cyclin-dependent kinase activating kinase/Cdk7 co-localizes with PKC-iota in human glioma cells.
Bicaku E; Patel R; Acevedo-Duncan M
Tissue Cell; 2005 Feb; 37(1):53-8. PubMed ID: 15695176
[TBL] [Abstract][Full Text] [Related]
30. Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase.
Aprelikova O; Xiong Y; Liu ET
J Biol Chem; 1995 Aug; 270(31):18195-7. PubMed ID: 7629134
[TBL] [Abstract][Full Text] [Related]
31. Formation of p27-CDK complexes during the human mitotic cell cycle.
Soos TJ; Kiyokawa H; Yan JS; Rubin MS; Giordano A; DeBlasio A; Bottega S; Wong B; Mendelsohn J; Koff A
Cell Growth Differ; 1996 Feb; 7(2):135-46. PubMed ID: 8822197
[TBL] [Abstract][Full Text] [Related]
32. Gambogic acid-induced G2/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells.
Yu J; Guo QL; You QD; Zhao L; Gu HY; Yang Y; Zhang HW; Tan Z; Wang X
Carcinogenesis; 2007 Mar; 28(3):632-8. PubMed ID: 17012222
[TBL] [Abstract][Full Text] [Related]
33. Structural basis for CDK7 activation by MAT1 and Cyclin H.
Peissert S; Schlosser A; Kendel R; Kuper J; Kisker C
Proc Natl Acad Sci U S A; 2020 Oct; 117(43):26739-26748. PubMed ID: 33055219
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome.
Kapasi AJ; Spector DH
J Virol; 2008 Jan; 82(1):394-407. PubMed ID: 17942543
[TBL] [Abstract][Full Text] [Related]
35. Dual phosphorylation of the T-loop in cdk7: its role in controlling cyclin H binding and CAK activity.
Martinez AM; Afshar M; Martin F; Cavadore JC; Labbé JC; Dorée M
EMBO J; 1997 Jan; 16(2):343-54. PubMed ID: 9029154
[TBL] [Abstract][Full Text] [Related]
36. Secrets of a double agent: CDK7 in cell-cycle control and transcription.
Fisher RP
J Cell Sci; 2005 Nov; 118(Pt 22):5171-80. PubMed ID: 16280550
[TBL] [Abstract][Full Text] [Related]
37. Regulation of CDK7-carboxyl-terminal domain kinase activity by the tumor suppressor p16(INK4A) contributes to cell cycle regulation.
Nishiwaki E; Turner SL; Harju S; Miyazaki S; Kashiwagi M; Koh J; Serizawa H
Mol Cell Biol; 2000 Oct; 20(20):7726-34. PubMed ID: 11003668
[TBL] [Abstract][Full Text] [Related]
38. Chemical transformation of mouse liver cells results in altered cyclin D-CDK protein complexes.
Gonzales AJ; Goldsworthy TL; Fox TR
Carcinogenesis; 1998 Jun; 19(6):1093-102. PubMed ID: 9667749
[TBL] [Abstract][Full Text] [Related]
39. The plant-specific kinase CDKF;1 is involved in activating phosphorylation of cyclin-dependent kinase-activating kinases in Arabidopsis.
Shimotohno A; Umeda-Hara C; Bisova K; Uchimiya H; Umeda M
Plant Cell; 2004 Nov; 16(11):2954-66. PubMed ID: 15486101
[TBL] [Abstract][Full Text] [Related]
40. Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery.
Fisher RP
Transcription; 2019 Apr; 10(2):47-56. PubMed ID: 30488763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
